Synergy Asset Management LLC Invests $63,000 in Pfizer Inc. (NYSE:PFE)

Synergy Asset Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,194 shares of the biopharmaceutical company’s stock, valued at approximately $63,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Quarry LP acquired a new position in Pfizer during the 2nd quarter worth approximately $31,000. Dana Investment Advisors Inc. lifted its position in shares of Pfizer by 9.6% during the 2nd quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock worth $2,803,000 after purchasing an additional 8,771 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in shares of Pfizer during the second quarter worth $118,000. Sanctuary Advisors LLC purchased a new position in Pfizer in the second quarter valued at $16,534,000. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its stake in Pfizer by 60.3% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 583,600 shares of the biopharmaceutical company’s stock valued at $16,329,000 after buying an additional 219,600 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.89 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $152.41 billion, a PE ratio of 36.34, a P/E/G ratio of 0.64 and a beta of 0.64. The stock has a fifty day moving average price of $26.22 and a 200 day moving average price of $27.90. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.40%. Pfizer’s payout ratio is presently 232.44%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.